OGEN | tickerfilter.com

Fundamental analysis

21%

Profitability 25%

Dept financing 5%

Liquidity 50%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

8.49%

1 Month

29.65%

3 Months

-7.78%

6 Months

-23.09%

1 Year

215.75%

2 Year

-38.36%

Key data

Stock price

$0.90

P/E Ratio

0.00

DAY RANGE

$0.84 - $0.94

EPS

-$5.69

52 WEEK RANGE

$0.11 - $7.60

52 WEEK CHANGE

$215.75

MARKET CAP

5.407 M

YIELD

N/A

SHARES OUTSTANDING

4.168 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-14-2025

BETA

1.89

PUBLIC FLOAT

AVERAGE 10 VOLUME

$211,959

AVERAGE 30 VOLUME

$435,362

Company detail

CEO: Kimberly M. Murphy
Region: US
Website: oragenics.com
Employees: 5
IPO year: 2004

Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Oragenics, Inc. develops antibiotics for infectious diseases in the United States. NT-CoV2-1, an intranasal vaccine candidate provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries.

OGEN - ORAGENICS INC